Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03779854 · ClinicalTrials.gov registry record · Phase 2
Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant
A Phase 2 study of Acute Lymphoblastic Leukemia and Acute Leukemia, sponsored by Fred Hutchinson Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 68
- Enrollment target
- 10
- Study locations
NCT03779854 is a Phase 2 study of Acute Lymphoblastic Leukemia and Acute Leukemia that is actively recruiting participants, run by Fred Hutchinson Cancer Center. The registered enrollment target is 68 participants, below the 382-participant average among 131 other Acute Lymphoblastic Leukemia trials with a reported enrollment target (82% lower). The trial reports 10 study locations across 9 states.
The verdict
NCT03779854, a Phase 2 study of Acute Lymphoblastic Leukemia and Acute Leukemia, is actively recruiting participants, sponsored by Fred Hutchinson Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 68 participants
- Enrollment target
- 10
- Study locations
Study Summary
This phase II trial studies how well naive T-cell depletion works in preventing chronic graft-versus-host disease in children and young adults with blood cancers undergoing donor stem cell transplant. Sometimes the transplanted white blood cells from a donor attack the body's normal tissues (called graft versus host disease). Removing a particular type of T cell (naive T cells) from the donor cells before the transplant may stop this from happening.
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- DRUG Busulfan
- RADIATION Total-Body Irradiation
- DRUG Thiotepa
Study Locations (10)
Ohio
- UH Rainbow Babies and Children's Hospital (University Hospitals Cleveland Medical Center) - Cleveland
- Cleveland Clinic Foundation - Cleveland
California
- Children's Hospital of Los Angeles - Los Angeles
District of Columbia
- Children's National Medical Center - Washington D.C.
Georgia
- Children's Healthcare of Atlanta - Atlanta
Iowa
- University of Iowa/Holden Comprehensive Cancer Center - Iowa City
Massachusetts
- Dana Farber / Boston Children's Hospital - Boston
Oregon
- Oregon Health and Science University - Portland
Pennsylvania
- Children's Hospital of Pittsburgh of UPMC - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2019-08-29 |
| Est. Completion | 2027-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03779854
The ClinicalTrials.gov registry entry for NCT03779854 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 68 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 382-participant average among 131 other Acute Lymphoblastic Leukemia trials with a reported enrollment target (82% lower). The listed sponsor is Fred Hutchinson Cancer Center, which has 483 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Acute Lymphoblastic Leukemia appearing as the primary indexed condition, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT03779854 reports 10 study locations spanning 9 distinct geographic areas - top geographies include Ohio, California, District of Columbia.
Frequently Asked Questions
What is clinical trial NCT03779854 about?
NCT03779854 is a clinical study titled "Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant". This phase II trial studies how well naive T-cell depletion works in preventing chronic graft-versus-host disease in children and young adults with blood cancers undergoing donor stem cell transplant. Sometimes the transplanted white blood cells from a donor attack the body's normal tissues (called ...
What is the current status of trial NCT03779854?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 68 participants. The study started on 2019-08-29. Estimated completion is 2027-12-31.
What conditions does trial NCT03779854 study?
This clinical trial studies the following conditions: Acute Lymphoblastic Leukemia, Acute Leukemia, Mixed Phenotype Acute Leukemia, Acute Biphenotypic Leukemia, Acute Leukemia of Ambiguous Lineage.
What interventions are being tested in trial NCT03779854?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), Busulfan (DRUG), Total-Body Irradiation (RADIATION), Thiotepa (DRUG).
Who is sponsoring clinical trial NCT03779854?
This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03779854 being conducted?
This trial has 10 study locations across California, District of Columbia, Georgia, Iowa, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Lymphoblastic Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)
RECRUITING · Phase 2
-
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
RECRUITING · Phase 2
-
Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases
RECRUITING · Phase 2
-
Intrathecal Chemoprophylaxis to Prevent Neurotoxicity Associated With Blinatumomab Therapy for Acute Lymphoblastic Leukemia
RECRUITING · Phase 2
-
MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies
RECRUITING · Phase 2
-
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.